Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Patent
1999-12-03
2000-12-19
Lambkin, Deborah C.
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
549 58, 549 49, 568632, 568633, 568327, 568328, 514443, C07D33356, C07D33352, C07C 4100, C07C 49115
Patent
active
061629308
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to the field of tubulin polymerization inhibitors. More particularly, it concerns the use of 3-aroyl-2-aryl-benzo[b]thiophenes and analogues thereof as anti-tumor agents.
2. Description of Related Art
An aggressive chemotherapeutic strategy toward the treatment and maintenance of solid-tumor cancers continues to rely on the development of architecturally new and biologically more potent anti-tumor, anti-mitotic agents. A variety of clinically-promising compounds which demonstrate potent cytotoxic and anti-tumor activity are known to effect their primary mode of action through an efficient inhibition of tubulin polymerization (Gerwick et al.). This class of compounds undergoes an initial binding interaction to the ubiquitous protein tubulin which in turn arrests the ability of tubulin to polymerize into microtubules which are essential components for cell maintenance and cell division (Owellen et al.).
Currently the most recognized and clinically useful tubulin polymerization inhibitors for the treatment of cancer are vinblastine and vincristine (Lavielle, et al.). Additionally, the natural products rhizoxin (Nakada, et al., 1993a and 1993b; Boger et al.; Rao et al., 1992 and 1993; Kobayashi et al., 1992 and 1993) combretastin A-4 and A-2 (Lin et al.; Pettit, et al., 1982, 1985, and 1987) and taxol (Kingston et al.; Schiff et al; Swindell, et a, 1991; Parness, et al.) as well as certain synthetic analogues including the 2-styrylquinazolin-4(3H)-ones (SQO) (Jiang et al.) and highly oxygenated derivatives of cis- and trans-stilbene (Cushman et al.) and dihydrostilbene are all known to mediate their cytotoxic activity through a binding interaction with tubulin. The exact nature of this interaction remains unknown and most likely varies somewhat between the series of compounds.
Tubulin is a heterodimer of the globular .alpha. and .beta. tubulin subunits. A number of photoaffinity labeling reagents for tubulin have been developed and evaluated (Rao et al., 1992 and 1994; Chavan et al.; Sawada et al., 1991, 1993a and 1993b; Staretz et al.; Hahn et al; Wolff et al.; Floyd et al.; Safa et al.; Williams et al.). These reagents have identified three distinct small molecule binding sites on tubulin: the colchicine site, the vinblastine site and the maytansine/rhizoxin site. Additionally, a first generation rhizoxin-based photoaffinity labeling reagent has suggested binding to the Met-363-Lys-379 site on .beta.-tubulin (Sawada et al., 1993a), and a taxol-based reagent has been found to label the N-terminal 31 amino acid residues of .beta.-tubulin (Swindell et al, 1991 and 1994; Rao et al., 1994). Taxol itself is known to bind to polymerized microtubules, but not at distinct sites on the monomer subunits of tubulin (Kingston et al.; Schiff et al.; Swindell et al., 1991; Parness et al.).
The discovery of new antimitotic agents may result from the judicious combination of a molecular template which in appropriately substituted form (i.e. phenolic moieties, etc.) interacts with the estrogen receptor suitably modified with structural features deemed imperative for binding to the colchicine site on .beta.-tubulin (arylalkoxy groups, certain halogen substitutions, pseudo aryl ring stacking, etc.). The methoxy aryl functionality seems especially important for increased interaction at the colchicine binding site in certain analogs. (Shirai et al., D'Amato et al., Hamel, 1996). Recent studies have shown that certain estrogen receptor (ER) binding compounds as structurally modified congeners (2-methoxyestradiol, for example) interact with tubulin and inhibit tubulin polymerization. (D'Amato et al., Cushman et al., 1995, Hamel, et al., 1996, Cushman et al., 1997). Estradiol is, of course, perhaps the most important estrogen in humans, and it is intriguing and instructive that the addition of the methoxy aryl motif to this compound makes it interactive with tubulin. As a steroid, however, the use of 2-methoxyestradiol as an anti-cancer ag
REFERENCES:
patent: 5886025 (1999-03-01), Pinney
patent: 6030986 (2000-02-01), Palkowitz
patent: 6040309 (2000-03-01), Dack et al.
patent: 6048875 (2000-04-01), De Manteuil et al.
patent: 6060488 (2000-05-01), Dodge et al.
Mejia Maria del Pilar
Mocharla Vani P.
Pettit George R.
Pinney Kevin G.
Shirali Anupama
Baylor University
Lambkin Deborah C.
LandOfFree
Anti-mitotic agents which inhibit tubulin polymerization does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-mitotic agents which inhibit tubulin polymerization, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-mitotic agents which inhibit tubulin polymerization will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-272234